Merck KGaA Partners with ICR and Wellcome Trust to Develop Anti-Cancer Drugs

Merck KGaA have today announced a new partnership with the Institute of Cancer Research (ICR) and the Wellcome Trust to develop cancer treatments. Merck KGaA’s Merck Serono unit will work with the UK organisations to identify inhibitors of tankyrase, an enzyme of the poly (ADP-ribose) polymerase (PARP) enzyme family. Specifically, the Institute of Cancer Research

Continue Reading